Pressure BioSciences, Inc. CEO, Ric Schumacher, Rejoins “Stock Day”, Very Optimistic About His Company’s Growth and Success in 2018 and Beyond
PHOENIX, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Mr. Richard T. Schumacher, CEO and President of Pressure BioSciences, Inc. (OTCQB:PBIO) (the “Company”) returns to the “Stock Day” podcast for the first time since the Company’s acquisition of all of the assets of BaroFold Corporation. Mr. Schumacher explained that the acquisition had increased the intellectual property estate of PBIO by eight issued and several pending patents, and had allowed PBIO to offer a number of important new applications to its worldwide base of nearly 200 customers with PBIO instrumentation.
Mr. Schumacher also discussed the newly established Center of Excellence in China, headed by Dr. Tiannan Guo of the Westlake Institute for Advanced Study. Dr. Guo and his team will use the Company’s instrumentation and consumables to focus on the processes of protein expression where clinical samples require precise purity, the perfect niche for PBIO’s patented Pressure Cycling Technology (“PCT”). Mr. Schumacher is excited to share that this Center of Excellence will showcase three of PBIO’s PCT instruments and many related consumable products. Being the first Center of Excellence in Asia, the Company will focus on the Chinese biopharmaceutical and biological research markets where there is a large community of bioscience engineers and scientists and centers for biotechnology advancements.
Mr. Schumacher reported to Mr. Jolly, CEO and Host of “Stock Day”, that Pressure BioSciences, Inc. sold more PCT machines in the 3rd quarter of 2017 than the Company had ever sold in one quarter before. Revenues for PBIO’s products and services, Mr. Schumacher reported, “Increased 21% just in that quarter alone, with consumable products increasing 158%, which was by far the largest increase in consumables we had ever reported.” With the 4th quarter typically being a weaker quarter for the Company due to the holidays, Mr. Schumacher nonetheless told Mr. Jolly that he had previously given guidance that Q4 2017 revenue could be the best fourth quarter revenue in the Company’s history.
Together with these achievements, the Company also made significant improvements to the software in their instrumentation product line. Mr. Schumacher explained that a billion dollar multinational company, who was a customer, had been working with Pressure BioSciences Inc. to produce a software upgrade for their flagship Barocycler 2320EXTREME instrument. With its new USB downloading capabilities to allow for regulatory compliance data tracking as well as compliance with important Good Manufacturing Practices (“GMP”), the Company believes this instrument will now be highly desirable in their niche life sciences and pharmaceutical markets. With a recently hired and trained salesforce in the field, the new BaroFold IP and technology, advanced software, and a new Center of Excellence in Asia, Mr. Schumacher anticipates 2018 as being a “banner year” for Pressure BioSciences.
To listen to the entire interview and hear more on the 2018 plan of action listen here: https://upticknewswire.com/featured-interview-ceo-ric-schumacher-of-pressure-biosciences-inc-otcqb-pbio-2
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. http://www.pressurebiosciences.com
About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona with its new host Kathryn Donnelly.
Investors Hangout is a sponsor of “Stock Day”. Uptick Newswire encourages listeners to visit About Pressure BioSciences, Inc. on: https://investorshangout.com/Pressure-Biosciences-PBIO-55055/
Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Richard T. Schumacher, President & CEO
Pressure BioSciences, Inc.
Nathan P. Lawrence, Ph.D., VP of Marketing and Sales
(508) 230-1828 (T)
Source: Uptick NewswireSource: Pressure BioSciences, Inc.
Released January 29, 2018